Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Journal for ImmunoTherapy of Cancer

Volumn 7, Issue 1, 2019, Pages

  Zheng, Yi ^a   Wang, Tingting ^b   Tu, Xiaoxuan ^a   Huang, Yun ^b   Zhang, Hangyu ^a   Tan, Di ^b   Jiang, Weiqin ^a   Cai, Shunfeng ^b   Zhao, Peng ^a   Song, Ruixue ^b   Li, Peilu ^b   Qin, Nan ^b,c   Fang, Weijia ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Realbio Genomics Institute   (China)

^c TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Anti PD 1 immunotherapy; Gut microbiome; Hepatocellular carcinoma

Indexed keywords

CAMRELIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; SHR 1210; SORAFENIB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

AKKERMANSIA MUCINIPHILA; ARTICLE; BACTERIUM IDENTIFICATION; BIOLOGICAL ACTIVITY; CANCER IMMUNOTHERAPY; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DIETARY INTAKE; DISEASE EXACERBATION; DNA EXTRACTION; FECES ANALYSIS; FECES MICROFLORA; GENE SEQUENCE; GENETIC PROFILE; HUMAN; LIVER CELL CARCINOMA; METABOLISM; METAGENOMICS; METHANOGENESIS; PRIORITY JOURNAL; PROTEOBACTERIA; RUMINOCOCCACEAE; TAXONOMY; TREATMENT PLANNING; BACTERIUM; CLASSIFICATION; CLINICAL DECISION MAKING; DNA SEQUENCE; DRUG EFFECT; GENETICS; IMMUNOTHERAPY; INTESTINE FLORA; ISOLATION AND PURIFICATION; LIVER TUMOR; MICROBIOLOGY; PHYLOGENY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; BACTERIA; CARCINOMA, HEPATOCELLULAR; CLINICAL DECISION-MAKING; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; METAGENOMICS; PHYLOGENY; PROGRAMMED CELL DEATH 1 RECEPTOR; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 85069795167     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-019-0650-9     Document Type: Article

References (25)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology. 2009;10(1):25-34.
3. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (London, England). 2017;389(10088):2492-502.
4. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. The Lancet Oncology. 2018;19(7):940-52.
5. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104.
6. Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-84.
7. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
8. Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7.
9. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207-14.
10. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-9.
11. Shoaie S, Ghaffari P, Kovatcheva-Datchary P, Mardinoglu A, Sen P, Pujos-Guillot E, et al. Quantifying diet-induced metabolic changes of the Human gut Microbiome. Cell Metab. 2015;22(2):320-31.
12. Chung WSF, Meijerink M, Zeuner B, Holck J, Louis P, Meyer AS, et al. Prebiotic potential of pectin and pectic oligosaccharides to promote anti-inflammatory commensal bacteria in the human colon. FEMS Microbiol Ecol. 2017;1, 93(11).
13. Zhang X, Li N, Shao H, Meng Y, Wang L, Wu Q, et al. Methane limit LPS-induced NF-kappaB/MAPKs signal in macrophages and suppress immune response in mice by enhancing PI3K/AKT/GSK-3beta-mediated IL-10 expression. Sci Rep. 2016;6:29359.
14. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334(6052):105-8.
15. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, et al. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439.
16. Fritz JV, Desai MS, Shah P, Schneider JG, Wilmes P. From meta-omics to causality: experimental models for human microbiome research. Microbiome. 2013;1(1):14.
17. Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, et al. A metagenomic study of the gut microbiome in Behcet's disease. Microbiome. 2018;6(1):135.
18. Galloway-Pena JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, et al. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome medicine. 2017;9(1):21.
19. Fang C, Zhong H, Lin Y, Chen B, Han M, Ren H, et al. Assessment of the cPAS-based BGISEQ-500 platform for metagenomic sequencing. GigaScience. 2018;7(3):1-8.
20. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, et al. The UCSC genome browser database: 2015 update. Nucleic Acids Res. 2015;43(Database issue):D670-81.
21. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nat Methods. 2015;12(10):902-3.
22. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, et al. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014;32(8):834-41.
23. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome. Nucleic Acids Res. 2004;32(Database issue):D277-80.
24. Parks DH, Beiko RG. Measures of phylogenetic differentiation provide robust and complementary insights into microbial communities. The ISME Journal. 2013;7:173-83.
25. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12(6):R60.